Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

clan Feb. 11 at 3:52 PM

$NVS $JNJ $UNH 😲🚨 Anybody here know a diabetic who still injects their mealtime insulin? You might tell them about this INHALABLE type. #inhalemyinsulin #afrezza

0 · Reply

SpudZone Feb. 11 at 3:28 PM

$QQQ $SPY feels like we could fall off a cliff these next couple sessions, lot of marginal leverage could get wiped out again after Friday's over extended cat bounce. Defensive and dividend names flying... $BMY $GILD $JNJ

0 · Reply

clan Feb. 11 at 3:13 PM

$MNKD Nintedanib DPI It's coming! For the good of all Mannkind! $RHHBY $UTHR $JNJ

0 · Reply

Quantumup Feb. 11 at 1:51 PM

Stifel (a/o 2/9) reiterated $ACLX Buy/$127 $LEGN - $JNJ $BMY GILD Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2021582108808860118?s=20

0 · Reply

Suite510 Feb. 11 at 1:18 PM

$JNJ $KVUE Rocky Balboa time in Philly 🥊 Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps in Philadelphia 😂🥊

1 · Reply

Suite510 Feb. 10 at 10:50 PM

$JNJ $KVUE Here comes the right hook 🥊 🤣 A Sacred Cow’: Phila. Jury Deliberations Begin in Johnson & Johnson Baby Powder Talc Trial

0 · Reply

Armazi_Capital Feb. 10 at 10:24 PM

$JNJ $DRMA I really like this sort of speculation, and how the article is written. Interesting.....

0 · Reply

RumoredbuyoutDeals Feb. 10 at 9:55 PM

$JNJ Potentially Buying $DRMA https://cafepharma.com/boards/threads/jnj-potentially-buying-dermata-therapeutics-nasdaq-drma-a-san-diego%E2%80%93based-dermatology-company.714762/#gsc.tab=0

0 · Reply

ballantine Feb. 10 at 8:55 PM

$ASML $JNJ $MA $NVDA $XOM you’ve lost your mind today and who knows how long,why are you clogging up this site? I see the replies

0 · Reply

houthis4justice Feb. 10 at 7:41 PM

$PLTR $SHIB.X $JNJ $INTC https://youtu.be/U_zWBOV_bng?si=MJRJeM8CwG76qWa2

0 · Reply

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 4 days ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 5 days ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 6 days ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 8 days ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 8 days ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 8 days ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 1, 2026, 10:35 AM EST - 9 days ago

Ariel Focus Fund Q4 2025 Portfolio Review

ADT AMG B FISV MOS ORCL

Jan 30, 2026, 2:43 PM EST - 11 days ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 7:19 AM EST - 12 days ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 12 days ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 12 days ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 28, 2026, 9:38 AM EST - 14 days ago

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 14 days ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 15 days ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 25, 2026, 10:11 PM EST - 16 days ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Jan 22, 2026, 12:15 AM EST - 20 days ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 20 days ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 20 days ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 20 days ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 20 days ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 21 days ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 21 days ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 21 days ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 21 days ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 21 days ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 21 days ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 22 days ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 23 days ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 23 days ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

$TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide$

Jan 14, 2026, 4:30 PM EST - 27 days ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 13, 2026, 8:00 AM EST - 4 weeks ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 2:40 AM EST - 4 weeks ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Jan 12, 2026, 6:32 PM EST - 4 weeks ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 2:06 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 7:40 AM EST - 4 weeks ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

Jan 10, 2026, 10:00 AM EST - 4 weeks ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 9:52 AM EST - 4 weeks ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Jan 9, 2026, 9:59 AM EST - 4 weeks ago

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 5:10 AM EST - 4 weeks ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 4 weeks ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 8:43 PM EST - 4 weeks ago

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:24 PM EST - 4 weeks ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 7, 2026, 8:00 AM EST - 5 weeks ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 6, 2026, 8:03 AM EST - 5 weeks ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

$Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma$

Jan 6, 2026, 6:52 AM EST - 5 weeks ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 2, 2026, 5:06 PM EST - 5 weeks ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Jan 2, 2026, 4:17 PM EST - 5 weeks ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Jan 2, 2026, 8:00 AM EST - 5 weeks ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Dec 31, 2025, 8:47 AM EST - 6 weeks ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

clan Feb. 11 at 3:52 PM

$NVS $JNJ $UNH 😲🚨 Anybody here know a diabetic who still injects their mealtime insulin? You might tell them about this INHALABLE type. #inhalemyinsulin #afrezza

0 · Reply

SpudZone Feb. 11 at 3:28 PM

0 · Reply

clan Feb. 11 at 3:13 PM

$MNKD Nintedanib DPI It's coming! For the good of all Mannkind! $RHHBY $UTHR $JNJ

0 · Reply

Quantumup Feb. 11 at 1:51 PM

Stifel (a/o 2/9) reiterated $ACLX Buy/$127 $LEGN - $JNJ $BMY GILD Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2021582108808860118?s=20

0 · Reply

Suite510 Feb. 11 at 1:18 PM

$JNJ $KVUE Rocky Balboa time in Philly 🥊 Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps in Philadelphia 😂🥊

1 · Reply

Suite510 Feb. 10 at 10:50 PM

$JNJ $KVUE Here comes the right hook 🥊 🤣 A Sacred Cow’: Phila. Jury Deliberations Begin in Johnson & Johnson Baby Powder Talc Trial

0 · Reply

Armazi_Capital Feb. 10 at 10:24 PM

$JNJ $DRMA I really like this sort of speculation, and how the article is written. Interesting.....

0 · Reply

RumoredbuyoutDeals Feb. 10 at 9:55 PM

$JNJ Potentially Buying $DRMA https://cafepharma.com/boards/threads/jnj-potentially-buying-dermata-therapeutics-nasdaq-drma-a-san-diego%E2%80%93based-dermatology-company.714762/#gsc.tab=0

0 · Reply

ballantine Feb. 10 at 8:55 PM

$ASML $JNJ $MA $NVDA $XOM you’ve lost your mind today and who knows how long,why are you clogging up this site? I see the replies

0 · Reply

houthis4justice Feb. 10 at 7:41 PM

$PLTR $SHIB.X $JNJ $INTC https://youtu.be/U_zWBOV_bng?si=MJRJeM8CwG76qWa2

0 · Reply

maikl_211 Feb. 10 at 4:13 PM

$JNJ $ASML $MA $NVDA $PLTR Tesla BlackBerry Polestar Apple Polestar sold 1,069 cars in the UK and Tesla 714. We are living through the transformation.

0 · Reply

maikl_211 Feb. 10 at 1:48 PM

$XOM $JNJ $ASML $MA $NVDA

0 · Reply

CatRocks Feb. 10 at 12:44 PM

$TYRA $URGN $JNJ $PFE $MRK bot account?

0 · Reply

NasdaqKnight Feb. 10 at 12:21 PM

Value is Back: While the broader index is +4% YTD, the “Dogs of the Dow” strategy (high dividend yield) is up +9.35% YTD. Standouts: $CVX, $VZ, $JNJ — crushing the benchmark. Investors are rotating into defensibility and yield, leaving the pure growth narrative behind. Income + safety is the theme of 2026 so far. If this is helpful to you, tap @NasdaqKnight

0 · Reply

OfficialStocktwitsUser Feb. 10 at 3:51 AM

$JNJ RSI: 91.74, MACD: 7.5501 Vol: 8.67, MA20: 224.90, MA50: 213.90 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JRatBullReturns Feb. 9 at 9:31 PM

$ABUS March 9th $MRNA $JNJ $NVAX

0 · Reply

ZacksResearch Feb. 9 at 6:26 PM

$JNJ just proved it can grow through a major patent cliff — and that’s not easy. Innovative Medicine sales rose 4.1% in 2025, topping $60B, even with Stelara's ZER LOE, as Darzalex and new drugs offset the pressure 🚀 See how JNJ pulled it off and what’s driving the growth here 👉 https://www.zacks.com/stock/news/2841213/jj-posts-innovative-medicine-growth-in-2025-amid-stelara-patent-loss?cid=sm-stocktwits-2-2841213-teaser-32650&ADID=SYND_STOCKTWITS_TWEET_2_2841213_TEASER_32650

0 · Reply

HydrogenH2 Feb. 9 at 6:09 PM

$JNJ $NVDA https://www.reuters.com/investigations/ai-enters-operating-room-reports-arise-botched-surgeries-misidentified-body-2026-02-09/

1 · Reply

ZacksResearch Feb. 9 at 5:26 PM

$JNJ's 2025 resilience: Is the worst behind or just ahead? 🤔 Despite a sharp 41.3% drop in Stelara sales due to LOE, J&J's Innovative Medicine segment, for the first time, hit over $60B in full-year sales in 2025, powered by a 23% rise in Darzalex sales and strong new drug contributions. Yet, 2026 looms with more generic challenges for Stelara, Simponi, and Opsumit. Discover what this means for JNJ's growth ambitions 👉 https://www.zacks.com/stock/news/2841213/jj-posts-innovative-medicine-growth-in-2025-amid-stelara-patent-loss?cid=sm-stocktwits-2-2841213-body-32647&ADID=SYND_STOCKTWITS_TWEET_2_2841213_BODY_32647

0 · Reply

davidmoadel Feb. 9 at 5:00 PM

3 Safety-First Stocks That Can Help You Retire in Comfort -- article I wrote for @247WallSt https://247wallst.com/investing/2026/02/09/3-safety-first-stocks-that-can-help-you-retire-in-comfort/ $JNJ $BAC $AAPL

0 · Reply

clan Feb. 9 at 12:15 PM

$ELTP Forecast for last quarter @ upcoming Earnings Release: Elite Pharma - • Total Revenue: > $45M • EBITDA(norm.): > $25M ! • ELTP > $1.00/share 💊💰🤑 #pillpoppersunite $TEVA & $JNJ , look out!

0 · Reply

NasdaqKnight Feb. 9 at 10:03 AM

$JNJ — Geraldine Weiss strategy in action ✅ Apr 8, 2025: touched undervalued zone (~$142) 🚀 Vertical rally follows 🚨 Feb 2026: hits overvalued zone (~$240) If this is helpful to you, tap @NasdaqKnight +69% in under a year. Key lesson: buy quality when yield is high, hold through the upswing. Dividend-focused investing pays off — $JNJ is a textbook case of patience + fundamentals winning over hype. Real-time check: trading around $239.50 as of Feb 9, 2026, near all-time highs. Keep an eye on yield compression — signals when profit-taking may start.

0 · Reply

Market Cap	574.95B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.22
Forward PE	20.80
Profit Margin	28.46%
Debt to Equity Ratio	0.50

Volume	6,723,200
Avg Vol	8,683,978
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	83%
Beta	0.35
Analysts	Strong Sell
Price Target	$233.28